Tofacitinib (citrate) (Standard)

Tofacitinib (citrate) (Standard) is the analytical standard of Tofacitinib (citrate) . This product is intended for research and analytical applications. Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.

Product Specifications

CAS Number

[540737-29-9]

Product Name Alternative

Tasocitinib (citrate) (Standard) ; CP-690550 (citrate) (Standard)

UNSPSC

12352005

Hazard Statement

H302-H361

Target

Apoptosis; Bacterial; Fungal; Influenza Virus; JAK; Reference Standards

Type

Reference Standards

Related Pathways

Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tofacitinib-citrate-standard.html

Purity

99.92

Smiles

O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O

Molecular Formula

C22H28N6O8

Molecular Weight

504.49

Precautions

P264-P270-P280-P405-P501

References & Citations

[1]Jiang JK, et al. Examining the chirality, conformation and selective kinase inhibition of 3- ((3R,4R) -4-methyl-3- (methyl (7H-pyrrolo[2,3-d]pyrimidin-4-yl) amino) piperidin-1-yl) -3-oxopropanenitrile (CP-690,550) . J Med Chem. 2008 Dec 25;51 (24) :8012-8.|[2]Onda M, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014 Jul 1;193 (1) :48-55.|[3]LaBranche TP, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012 Nov;64 (11) :3531-42.|[4]Yagi K, et al. Pharmacological inhibition of JAK3 enhances the antitumor activity of STI571 in human chronic myeloid leukemia. Eur J Pharmacol. 2018 Apr 15;825:28-33.